<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412020000800002</article-id>
<article-id pub-id-type="doi">10.24245/gom.v88i8.2838</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Salpingooforectomía bilateral profiláctica en pacientes con BRCA1 o BRCA2]]></article-title>
<article-title xml:lang="en"><![CDATA[Prophylactic bilateral salpingo-oophorectomy in patients with BRCA1 or BRCA2]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Veiga-Fernández]]></surname>
<given-names><![CDATA[Amanda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Luque-Molina]]></surname>
<given-names><![CDATA[María del Sol]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferreres-García]]></surname>
<given-names><![CDATA[Karla]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendizábal-Vicente]]></surname>
<given-names><![CDATA[Elsa María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rincón-Olbes]]></surname>
<given-names><![CDATA[Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lizárraga-Bonelli]]></surname>
<given-names><![CDATA[Santiago]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Universitario Gregorio Marañón  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital General Universitario Gregorio Marañón  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<volume>88</volume>
<numero>8</numero>
<fpage>499</fpage>
<lpage>507</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412020000800002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412020000800002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412020000800002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  OBJETIVO:  Determinar la prevalencia, factores clínicos o epidemiológicos de cáncer oculto en pacientes BRCA1 o BRCA2 operadas para salpingooforectomía bilateral profiláctica. Evaluar las complicaciones quirúrgicas en las cirugías laparoscópicas.  MATERIALES Y MÉTODOS:  Estudio observacional, retrospectivo, llevado a cabo en el Hospital Gregorio Marañón entre 2012 y 2018. Se revisaron las salpingooforectomías bilaterales profilácticas practicadas a pacientes con mutaciones confirmadas BRCA1 o 2, no diagnosticadas previamente de cáncer de ovario o trompa. Las principales variables analizadas fueron: antecedentes familiares, edad, índice de masa corporal, hábito tabáquico, mutación genética, cirugías abdominales previas, cáncer de mama, fecha de la cirugía, tiempo quirúrgico, tipo de cirugía, técnica de entrada a la cavidad abdominal y complicaciones quirúrgicas. El análisis estadístico se efectuó con SPSS 17.0.  RESULTADOS:  Se estudiaron 59 pacientes. La prevalencia de cáncer oculto fue 5 de 59. La edad media de las pacientes con diagnóstico de cáncer oculto en el momento de la cirugía fue 47.8 años. Se encontró antecedente de cáncer de mama en 43 de las 59 pacientes; en este subgrupo se encontró cáncer oculto en 2 pacientes. En el subgrupo sin antecedente de cáncer de mama, la frecuencia fue 3 de 16. No se encontraron diferencias estadísticamente significativas entre ambos grupos (p = 0.118). Todas las pacientes a quienes se diagnosticó cáncer oculto, salvo una, eran fumadoras. La tasa de complicaciones intraoperatorias fue 2 de 51 y 1 de 51 las postoperatorias  CONCLUSIONES:  Las pacientes con BRCA1 o BRCA2 son un grupo de alto riesgo oncológico que requiere seguimiento y asesoramiento específicos en unidades especializadas de hospitales de tercer nivel de atención.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  OBJECTIVE:  To determine the prevalence of occult cancer in BRCA1 and/or BRCA2 patients undergoing prophylactic bilateral salpingo-oophorectomy. To determine associated clinical or epidemiological factors. To evaluate surgical complications in surgeries performed via laparoscopy.  MATERIAL AND METHODS:  Retrospective observational study conducted at the Gregorio Marañón hospital between 2012 and 2018. Review of prophylactic bilateral salpingo-oophorectomies performed in patients with confirmed BRCA1 and/or 2 mutations and not previously diagnosed with ovarian and/or fallopian cancer. Main variables: family history, age, body mass index, smoking habit, genetic mutation, previous abdominal surgeries, breast cancer, surgery date, surgical time, type of surgery, technique of the entrance to the abdominal cavity, surgical complications. The statistical analysis was performed using SPSS 17.0.  RESULTS:  59 patients were included. The prevalence of occult cancer was 5/59. The average age (at the time of surgery) of patients diagnosed with occult cancer was 47.8 years. 43/59 had a history of breast cancer; in this group occult cancer was found in two patients. In the group with no history of breast cancer, frequency of occult cancer was 3/16. No statistically significant differences were found between both groups (p = 0.118). All patients diagnosed with occult cancer, except one, were smokers. The rate of intraoperative complications was 2/51 and 1/51 postoperative.  CONCLUSIONS:  Patients with BRCA1 and/or BRCA2 mutations are a group of high cancer risk that require specific monitoring and advice in specialized units of third level hospitals.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[BRCA1]]></kwd>
<kwd lng="es"><![CDATA[BRCA2]]></kwd>
<kwd lng="es"><![CDATA[prevalencia]]></kwd>
<kwd lng="es"><![CDATA[salpingooforectomía bilateral]]></kwd>
<kwd lng="es"><![CDATA[laparoscopia]]></kwd>
<kwd lng="es"><![CDATA[detección de mutaciones]]></kwd>
<kwd lng="es"><![CDATA[cavidad abdominal]]></kwd>
<kwd lng="es"><![CDATA[estudios retrospectivos]]></kwd>
<kwd lng="en"><![CDATA[Prevalence]]></kwd>
<kwd lng="en"><![CDATA[BRCA1]]></kwd>
<kwd lng="en"><![CDATA[BRCA2]]></kwd>
<kwd lng="en"><![CDATA[Bilateral salpingo- oophorectomy]]></kwd>
<kwd lng="en"><![CDATA[Laparoscopy]]></kwd>
<kwd lng="en"><![CDATA[Cancer mutations]]></kwd>
<kwd lng="en"><![CDATA[Abdominal cavity]]></kwd>
<kwd lng="en"><![CDATA[Retrospective studies]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1]]></article-title>
<source><![CDATA[Science]]></source>
<year>1994</year>
<volume>266</volume>
<page-range>66-71</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wooster]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of the breast cancer susceptibility gene BRCA2]]></article-title>
<source><![CDATA[Nature]]></source>
<year>1995</year>
<volume>378</volume>
<page-range>789-92</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Finch]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2006</year>
<volume>296</volume>
<page-range>185-92</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Antoniou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history a combined analysis of 22 studies]]></article-title>
<source><![CDATA[Am J Human Genet]]></source>
<year>2003</year>
<volume>72</volume>
<page-range>1117-30</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families The Breast Cancer Linkage Consortium]]></article-title>
<source><![CDATA[Am J Hum Genet]]></source>
<year>1998</year>
<volume>62</volume>
<page-range>676-89</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Struewing]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1997</year>
<volume>336</volume>
<page-range>1401-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gayther]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene]]></article-title>
<source><![CDATA[Nat Genet]]></source>
<year>1997</year>
<volume>15</volume>
<page-range>103-5</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burke]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for follow-up care of individuals with an inherited predisposition to cancer II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1997</year>
<volume>277</volume>
<page-range>997-1003</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening for ovarian cancer a pilot randomised controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1999</year>
<volume>353</volume>
<page-range>1207-10</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Nagell]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2000</year>
<volume>77</volume>
<page-range>350-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laframboise]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of CA-125 and ultrasound in high-risk women]]></article-title>
<source><![CDATA[Int J Gynecol Cancer]]></source>
<year>2002</year>
<volume>12</volume>
<page-range>86-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rebbeck]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2002</year>
<volume>346</volume>
<page-range>1616-22</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kauff]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2002</year>
<volume>346</volume>
<page-range>1609-15</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Finch]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers]]></article-title>
<source><![CDATA[Gyn Oncol]]></source>
<year>2006</year>
<volume>100</volume>
<page-range>58-64</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Powell]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk-reducing salpingo-oophorectomy in BRCA mutation carriers role of serial sectioning in the detection of occult malignancy]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2005</year>
<volume>23</volume>
<page-range>127-32</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kauff]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 of BRCA2]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2007</year>
<volume>25</volume>
<page-range>2921-7</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kauff]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multi-centre prospective analysis of risk reducing salpingoophorectomy to prevent BRCA-associated breast and ovarian cancer]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2006</year>
<volume>24</volume>
<page-range>49S</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2000</year>
<volume>18</volume>
<page-range>2728-32</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carcangiu]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions report of 6 cases and review of the literature]]></article-title>
<source><![CDATA[Am J Surg Pathol]]></source>
<year>2006</year>
<volume>30</volume>
<page-range>1222-30</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary carcinoma of the fallopian tube. A report of 19 cases with literature review]]></article-title>
<source><![CDATA[Eur J Gynaecol Oncol]]></source>
<year>2000</year>
<volume>21</volume>
<page-range>578-82</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivier]]></surname>
<given-names><![CDATA[RI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up]]></article-title>
<source><![CDATA[British Journal of Cancer]]></source>
<year>2004</year>
<volume>90</volume>
<page-range>1492-7</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schubert]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2]]></article-title>
<source><![CDATA[Am J Hum Genet]]></source>
<year>1997</year>
<volume>60</volume>
<page-range>1031-40</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tong]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization]]></article-title>
<source><![CDATA[Clin Chem]]></source>
<year>1999</year>
<volume>45</volume>
<page-range>976-81</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartley]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery]]></article-title>
<source><![CDATA[Clin Oncol (R Coll Radiol)]]></source>
<year>2000</year>
<volume>12</volume>
<page-range>58-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rose]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Germline BRCA2 mutation in a patient with fallopian tube carcinoma a case report]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2000</year>
<volume>77</volume>
<page-range>319-20</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sobol]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fallopian tube cancer as a feature of BRCA1-associated syndromes]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2000</year>
<volume>78</volume>
<page-range>263-4</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zweemer]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2000</year>
<volume>76</volume>
<page-range>45-50</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agoff]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unexpected gynecologic neoplasms in patients with proven or suspected BRCA1 or -2 mutations implications for gross examination, cytology, and clinical follow-up]]></article-title>
<source><![CDATA[Am J Surg Pathol]]></source>
<year>2002</year>
<volume>26</volume>
<page-range>171-8</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hirst]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy]]></article-title>
<source><![CDATA[Int J Gynecol Cancer]]></source>
<year>2009</year>
<volume>19</volume>
<page-range>826-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Boyle]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Laparoscopic oophorectomy: description and report of an initial series]]></article-title>
<source><![CDATA[Br J Surg]]></source>
<year>1996</year>
<volume>83</volume>
<page-range>986</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Willsher]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Laparoscopic oophorectomy in the management of breast disease ANZ J]]></article-title>
<source><![CDATA[Surg]]></source>
<year>2008</year>
<volume>78</volume>
<page-range>670-2</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
